Mild-to-Moderate Ulcerative Colitis Guideline

Cross, Raymond; Ko, Cynthia W.; Singh, Siddharth

doi:10.1053/j.gastro.2019.01.037

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The UC lesions are concentrated mainly in the rectum and sigmoid colon, and the whole colon in severe cases. UC is characterized by clinical manifestations such as diarrhea, abdominal pain, mucus pus, bloody stools, and other symptoms (1). Immune abnormalities, genetic susceptibility, and intestinal microbial function are the principal pathogenic factors in UC (2).…”

Section: Introductionmentioning

confidence: 99%

Geniposide attenuates dextran sulfate sodium-induced colitis in mice via Nrf-2/HO-1/NF-κB pathway

Yang¹,

Yue²,

Li³

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: Geniposide (GE) is the main component in gardenia fruit. This study aimed to investigate the protective effects and potential mechanisms of GE on dextran sulfate sodium (DSS)-induced colitis in mice and lipopolysaccharide (LPS)-induced RAW 264.7 cells. Methods:The in vivo acute colitis experimental model was established by administering drinking water containing 3% DSS to the mice for 7 days. GE was administered to the mice via oral gavage at 20 and 40 mg/kg for 7 days. Colon length, colon myeloperoxidase (MPO) level, serum and colon malondialdehyde (MDA) levels, and superoxide dismutase (SOD) activity were determined, and histological evaluation was performed. The levels of interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-α (TNF-α) in the serum and colon were detected. The expression of proteins of the nuclear factor E2 related factor 2 (Nrf-2)/HO-1/ NF-κB pathway in the colon was detected. The in vitro model of LPS-induced RAW 264.7 cells to simulate enteritis model. Cell viability, IL-6, IL-1β, and TNF-α levels in the cell supernatant were measured. The MPO levels in RAW 264.7 cells and DSS-induced mice and MDA and SOD levels in the cell supernatant were measured. The expression of proteins of the Nrf-2/HO-1/NF-κB pathway in RAW 264.7 cells was determined.Results: GE treatment resulted in significant histological changes and reduced the expression of inflammatory mediators IL-6, IL-1β, and TNF-α the in serum, colon, and cell supernatant effectively.Parenteral nutrition reduced MPO content in the colon and RAW 264.7 cells. GE treatment increased SOD levels in the serum, colon, and cell supernatant. GE restored the protein expression of the Nrf-2/HO-1/ NF-κB pathway in RAW 264.7 cells and nude mice, and these changes were blocked significantly by Nrf-2 siRNA.Conclusions: These findings demonstrated that GE ameliorated inflammation and oxidative stress in experimental colitis via modulation of the Nrf-2/HO-1/NF-κB pathway. Thus, GE could serve as a potential therapeutic agent for the treatment of ulcerative colitis (UC).

show abstract

Section: Introductionmentioning

confidence: 99%

Geniposide attenuates dextran sulfate sodium-induced colitis in mice via Nrf-2/HO-1/NF-κB pathway

Yang¹,

Yue²,

Li³

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts Inflammatory bowel disease (IBD) severity is used by IBD providers, industry, and payers to align around critical care concepts including risk stratification (likelihood of progression, complications and poor outcomes) and treatment decision making (e.g., does the patient's disease severity warrant a biologic?) Treatment decisions based on disease severity (mild-to-moderate or moderate-to-severe) are supported by national guidelines and best practice documents [1][2][3][4][5] and shared-decision aids that translate these concepts to patientsincluding the relative risk of developing IBD complications and benefits of early effective treatment-have been shown to positively impact outcomes. 6 Does disease severity, as currently defined, go far enough in predicting who is at risk for poor outcomes in IBD?…”

Section: N V I T E D E D I T O R I a Lmentioning

confidence: 99%

Editorial: measuring disease severity in inflammatory bowel disease—the whole is greater than the sum of its parts

Keefer

Shapiro

2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The majority of patients with UC have a mild disease that is mainly treated with 5-aminosalicylic acid (5-ASA), whereas patients with severe disease require hormone-induced remission ( 4 , 5 ). It can change the transcription of inflammatory genes, and play anti-inflammatory and immunosuppressive roles, therefore it is the preferred therapeutic drug for patients with severe UC ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

“…It can change the transcription of inflammatory genes, and play anti-inflammatory and immunosuppressive roles, therefore it is the preferred therapeutic drug for patients with severe UC ( 4 ). However, in some patients, the oral drugs reach the distal colon, i.e., the second colon, or even part of the descending colon, at a low concentration, which makes it difficult to exert the efficacy and this is the site where UC is most likely to occur ( 5 ). Suppositories can only act on the rectal mucosa, so the inflammation of the distal colonic mucosa is often prolonged ( 1 , 2 ).…”

Section: Introductionmentioning

confidence: 99%

Pulsatilla decoction alleviates colitis by enhancing autophagy and regulating PI3K‑Akt‑mTORC1 signaling pathway

Wang

et al. 2022

Mol Med Rep

View full text Add to dashboard Cite

The aim of the present study was to investigate the therapeutic effect of Pulsatilla decoction (PD) on ulcerative colitis (UC) and to elucidate its potential molecular mechanisms. C57BL/6 mice expressing natural killer (NK)1.1 were used as experimental animals in the present study and a model of oxazolone-induced colitis was established. Mice were randomly divided into the following five groups: i) PD group; ii) oxazolone-induced colitis group; iii) IL-13 intervention group; iv) 5-aminosalicylic acid positive control group; and v) negative control group (equal volume saline gavage). A total of 10 animals were used in each group. The effects of PD on UC and the association between this regimen and the PI3K-Akt-mTORC1 signaling pathway were evaluated by disease activity index (DAI), hematoxylin and eosin staining, reverse transcription-quantitative PCR (RT-qPCR), immunofluorescence assay, ELISA and western blotting. The UC models were successfully established by injecting oxazolone gavage solution. Clinical colitis evaluation and histological examination revealed that PD reduced the DAI values in oxazolone-induced colitis in mice and the degree of infiltration in NK1.1 cells. PD significantly reduced the secretion of IL-13, as determined using an ELISA. In addition, western blotting and RT-qPCR analyses demonstrated that Beclin1 and LC3II/I expression levels were downregulated following treatment of the mice with PD. In addition, PD not only partially restored alterations in the expression of tight junction proteins in the colon tissues, but also suppressed the activation of the PI3K-Akt-mTORC1 signaling pathway. The data indicated that this regimen could alleviate oxazolone-induced UC in mice, which could significantly reduce tissue inflammation and autophagy. The mechanism of action was associated with the PI3K-Akt-mTORC1 signaling pathway.

show abstract

Mild-to-Moderate Ulcerative Colitis Guideline

Cited by 6 publications

References 0 publications

Geniposide attenuates dextran sulfate sodium-induced colitis in mice via Nrf-2/HO-1/NF-κB pathway

Geniposide attenuates dextran sulfate sodium-induced colitis in mice via Nrf-2/HO-1/NF-κB pathway

Editorial: measuring disease severity in inflammatory bowel disease—the whole is greater than the sum of its parts

Pulsatilla decoction alleviates colitis by enhancing autophagy and regulating PI3K‑Akt‑mTORC1 signaling pathway

Contact Info

Product

Resources

About